LTRN Earnings & Financial Statements
Lantern Pharma Inc.
$0.67
-$0.04(-5.30%)
20
Overall
40
Value
9
Tech
13
Quality
Market Cap
$10.05M
Volume
212.26K
52W Range
$0.76 - $4.58
Target Price
$25.00
LTRN earnings and financial statements: Lantern Pharma Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
LTRN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cost of revenue | - | - | $8.45M | - | - |
| Operating income | -$17.98M | -$22.22M | -$17.88M | -$14.43M | -$12.59M |
| EBITDA | -$17.10M | -$20.76M | -$15.95M | -$14.42M | -$12.58M |
| Net income | -$17.12M | -$20.78M | -$15.96M | -$14.26M | -$12.36M |
| EPS (diluted) | $-1.57 | $-1.93 | $-1.47 | $-1.31 | $-1.13 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $11.04M | $25.57M | $43.65M | $58.84M | $73.95M |
| Total liabilities | $4.50M | $4.38M | $2.74M | $2.80M | $2.38M |
| Shareholders’ equity | $6.53M | $21.19M | $40.91M | $56.04M | $71.57M |
| Cash and equivalents | $4.42M | $7.51M | $21.94M | $37.20M | $51.52M |
| Long-term debt | - | $52.8K | $61.5K | - | $52.9K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$15.68M | -$17.81M | -$14.35M | -$12.77M | -$10.59M |
| Capital expenditure | -$1.7K | -$12.6K | -$18.7K | -$27.8K | -$15.5K |
| Free cash flow | -$15.68M | -$17.83M | -$14.37M | -$12.80M | -$10.61M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LTRN | $0.67 | -5.3% | 212.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |